Fig 1: Quantification of RGS5 immunoreactivity. The expression of RGS5 at days 4 and 6of rh-ES-treated Lewis lung cancer tumors demonstrated a significant reduction compared with NS LLC tumors, whilst there was no significant difference at days 2 and 9 between the two groups. *P<0.05 vs. NS. RGS5, regulator of G-protein signaling 5; rh-ES, recombinant human endostatin; NS, normal saline.
Fig 2: Representative images showing RGS5 (a marker for tumor vascular normalization) immunohistochemistry staining in Lewis lung cancer tumors after treatment with rh-ES or NS for days 2, 4, 6 and 9. The positive RGS5 signals were located in the cytoplasm and had a color of light yellow to brown. Magnification, ×400. RGS5, regulator of G-protein signaling 5; rh-ES, recombinant human endostatin; NS, normal saline.
Fig 3: Reverse transcription-quantitative polymerase chain reaction demonstrating RGS5 mRNA levels in rh-ES and NSLLC tumors. RGS5 mRNA levels at days 4 and 6 of rh-ES-treated LLC tumors presented a significant reduction compared with saline-treated LLC tumors while there was no significant difference at days 2 and 9 between the two groups. *P<0.05 vs. NS. RGS5, regulator of G-protein signaling 5; rh-ES, recombinant human endostatin; LLC, Lewis lung cancer; NS, normal saline.
Fig 4: ELISA assay demonstrating RGS5 protein levels in rh-ES and NS LLC tumors. RGS5 protein levels at days 4 and 6 of rh-ES-treated LLC tumors presented a significant reduction compared with saline-treated LLC tumors, whilst there was no significant difference at days 2 and 9 between the two groups. *P<0.05 vs. NS.RGS5, regulator of G-protein signaling 5; rh-ES, recombinant human endostatin; LLC, Lewis lung cancer; NS, normal saline.
Supplier Page from MyBioSource.com for Mouse Regulator of G-protein signaling 5 (RGS5) ELISA Kit